This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
FederalRegister.gov retrieves relevant information about this document from Regulations.gov to provide users with additional context. This information is not part of the official Federal Register document.
Food and Drug Administration, HHS.
Notice; request for comments.
The Food and Drug Administration (FDA, the Agency, or we) is soliciting comments from the public on various topics pertaining to the regulation of cosmetics in preparation for the twentieth International Cooperation on Cosmetics Regulation annual meeting (ICCR-20). We may use this input to help us prepare for the ICCR-20 meeting that will be held July 7 to 9, 2026, in Tokyo, Japan.
Either electronic or written comments on this notice must be submitted by May 18, 2026.
You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The https://www.regulations.gov electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of May 18, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.
Submit electronic comments in the following way:
Submit written/paper submissions as follows:
Instructions: All submissions received must include the Docket No. FDA-2026-N-2279 for “Preparation for International Cooperation on Cosmetics Regulation Twentieth Annual Meeting (ICCR-20); Request for Comments.” Received comments, those filed in a timely manner (see ADDRESSES ), will be placed in the docket and, except for those submitted as “Confidential Submissions,” publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.
Deborah Smegal, Office of Cosmetics and Colors, Office of the Chief Scientist, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1818, Deborah.Smegal@fda.hhs.gov.
The intention of the International Cooperation on Cosmetics Regulation (ICCR) multilateral framework is to pave the way for the removal of regulatory obstacles to international trade while maintaining global consumer protection. FDA is soliciting comments from the public on various topics pertaining to the regulation of cosmetics. We may use this input to help us prepare for the twentieth ICCR annual meeting (ICCR-20) that will be held July 7 to 9, 2026, in Tokyo, Japan.
ICCR is a voluntary international group of cosmetics regulatory authorities, including the United States. These regulatory authority members will engage in dialogue with their relevant cosmetics industry trade associations and other interested parties. The current ICCR members can be found at: https://www.iccr-cosmetics.org/. The ICCR generally operates on a consensus-based decision-making process (see https://www.iccr-cosmetics.org/topics-documents/4-iccr-governance). All decisions will be compatible with the laws, policies, rules, regulations, and directives of the respective administrations and governments of the ICCR members. Members will implement and/or promote actions or documents within their own jurisdictions and seek convergence of regulatory policies and practices. Successful implementation will need input from interested parties.
ICCR considers various topics of common interest and relevance for cosmetics (see https://www.iccr-cosmetics.org/topics-documents).
FDA is requesting public comment on the following questions related to topics identified for the ICCR-20 meeting.[1] FDA is also requesting public comment on any additional cosmetics topics of interest for consideration by ICCR for future work.
1. What new International Organization for Standardization (ISO) standards and technical reports should be considered for inclusion in the Updated Annex of International Standards in Cosmetics Report (Ref. 1)?
2. What new non-animal testing methods should be considered for inclusion in the Inventory of Validated Non-Animal Testing Methods Applicable for Cosmetic Products and their Ingredients in all ICCR Regions (Ref. 2)?
3. What are your suggestions to help make risk assessment using non-animal data a more common approach for safety assessments of cosmetic ingredients?
4. What general principles should be considered for electronic labeling (e-labeling) and digital information for cosmetics across ICCR member jurisdictions?
5. What are common questions and misconceptions and ways to improve understanding related to cosmetics use, safety, and regulation that arise across ICCR member jurisdictions?
6. What are your suggestions for any changes to or considerations for ICCR's purpose, mission, and future direction?
The following references are on display at the Dockets Management Staff (see ADDRESSES ) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at https://www.regulations.gov. Although FDA verified the website addresses in this document, please note that websites are subject to change over time.
1. ICCR, “Updated Annex of International Standards in Cosmetics Report.” 2025. Accessed March 4, 2026. Available at: https://www.iccr-cosmetics.org/component/attachments/?task=download&id=181.
2. ICCR, “Inventory of Validated Non-Animal Testing Methods Applicable for Cosmetic Products and their Ingredients in all ICCR Regions.” 2025. Accessed March 4, 2026. Available at: https://www.iccr-cosmetics.org//downloads/topics/2025-updated%20annex%20of%20validated%20non-animal%20testing%20methods%20applicable%20for%20cosmetics.pdf.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
1. Topics for the ICCR-20 meeting were identified at the ICCR-19 meeting held on July 8 to 10, 2025, in Ottawa, Ontario, Canada. Outcomes of the ICCR-19 meeting are available at https://www.iccr-cosmetics.org/component/attachments/attachments?id=175&task=download.
Back to Citation[FR Doc. 2026-05280 Filed 3-17-26; 8:45 am]
BILLING CODE 4164-01-P
12 comments have been received at Regulations.gov.
Agencies review all submissions and may choose to redact, or withhold, certain submissions (or portions thereof). Submitted comments may not be available to be read until the agency has approved them.